Page 5 - Heart Failure Guidelines
P. 5

Pediatric Heart Failure Guidelines

               Neuromuscular Disorder Associated Cardiomyopathy ..............................................................25
                  Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .25

               Introduction ...............................................................................................................................25
               Initial Evaluation ........................................................................................................................25
               Ongoing Management ...............................................................................................................25

                  Dose escalation plan (outpatient monitoring) .........................................................................26
               Imaging .....................................................................................................................................27
               Arrhythmia Screening ................................................................................................................27
               Advanced Therapies .................................................................................................................27
               Myocarditis ................................................................................................................................28
                  Additional Evaluation for possible Myocarditis .......................................................................28
                  Medical Management Myocarditis .........................................................................................28
                  Immunotherapy Management Myocarditis .............................................................................28
                  Follow-up Schedule for Myocarditis .......................................................................................29

               Medication Doses .....................................................................................................................30
               Anticoagulation Schedules ........................................................................................................32
















































               Updated 5/17/2018                                                                       page 5
   1   2   3   4   5   6   7   8   9   10